

MIRAGEN THERAPEUTICS, INC.
Form 10-Q
November 07, 2018
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

FORM 10-Q

(Mark One)

QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2018

or

TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from _____ to _____

Commission File No. 001-36483

MIRAGEN THERAPEUTICS, INC.
(Exact name of registrant as specified in its charter)

Delaware 47-1187261
(State or other jurisdiction of (I.R.S. Employer
incorporation or organization) Identification No.)

6200 Lookout Road, Boulder, CO 80301
(Address, including zip code, of registrant's principal executive offices)

(720) 643-5200
(Registrant's telephone number, including area code)

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes No

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes No

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of "large accelerated filer," "accelerated filer," "smaller reporting company," and "emerging growth company" in Rule 12b-2 of the Exchange Act.

Large accelerated filer Accelerated filer
Non-accelerated filer Smaller reporting company
Emerging growth company

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act.

Indicate by check mark whether the registrant is a shell company (as defined in Rule 12b-2 of the Exchange Act). Yes No

As of October 31, 2018, there were 30,839,463 shares of the registrant's Common Stock outstanding.

MIRAGEN THERAPEUTICS, INC.
INDEX

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

<u>Condensed Consolidated Balance Sheets as of September 30, 2018 and December 31, 2017 (Unaudited)</u>	<u>4</u>
<u>Condensed Consolidated Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2018 and 2017 (Unaudited)</u>	<u>5</u>
<u>Condensed Consolidated Statements of Changes in Stockholders' Equity for the nine months ended September 30, 2018 (Unaudited)</u>	<u>6</u>
<u>Condensed Consolidated Statements of Cash Flows for the nine months ended September 30, 2018 and 2017 (Unaudited)</u>	<u>7</u>
<u>Notes to Condensed Consolidated Financial Statements (Unaudited)</u>	<u>8</u>
<u>Item 2. Management's Discussion and Analysis of Financial Condition and Results of Operations</u>	<u>29</u>
<u>Item 3. Quantitative and Qualitative Disclosures about Market Risk</u>	<u>35</u>
<u>Item 4. Controls and Procedures</u>	<u>36</u>

PART II. OTHER INFORMATION

<u>Item 1. Legal Proceedings</u>	<u>37</u>
<u>Item 1A. Risk Factors</u>	<u>37</u>
<u>Item 2. Unregistered Sales of Equity Securities and Use of Proceeds</u>	<u>69</u>
<u>Item 3. Defaults Upon Senior Securities</u>	<u>69</u>
<u>Item 4. Mine Safety Disclosures</u>	<u>69</u>
<u>Item 5. Other Information</u>	<u>69</u>
<u>Item 6. Exhibits</u>	<u>69</u>

Table of Contents

PART I. FINANCIAL INFORMATION

ITEM 1. FINANCIAL STATEMENTS

MIRAGEN THERAPEUTICS, INC.
 CONDENSED CONSOLIDATED BALANCE SHEETS
 (in thousands, except share and per share data)
 (unaudited)

	September 30, 2018	December 31, 2017
Assets		
Current assets:		
Cash and cash equivalents	\$ 31,700	\$ 47,441
Short-term investments	38,827	—
Accounts receivable	1,382	1,456
Prepaid expenses and other current assets	3,843	2,971
Total current assets	75,752	51,868
Property and equipment, net	751	563
Other assets	50	50
Total assets	\$ 76,553	\$ 52,481
Liabilities and Stockholders' Equity		
Current liabilities:		
Accounts payable	\$ 1,206	\$ 906
Accrued liabilities	4,336	2,991
Current portion of note payable	1,291	—
Total current liabilities	6,833	3,897
Note payable, net of current portion	8,914	9,922
Other liabilities	88	152
Total liabilities	15,835	13,971
Commitments and contingencies		
Stockholders' equity:		
Common stock, \$0.01 par value; 100,000,000 shares authorized; 30,833,367 and 22,568,006 shares issued and outstanding at September 30, 2018 and December 31, 2017, 308 respectively		226
Additional paid-in capital	176,395	131,877
Accumulated other comprehensive loss	(6) —
Accumulated deficit	(115,979) (93,593
Total stockholders' equity	60,718	38,510
Total liabilities and stockholders' equity	\$ 76,553	\$ 52,481

See accompanying notes to these condensed consolidated financial statements.

4

Table of Contents

MIRAGEN THERAPEUTICS, INC.

CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONS AND COMPREHENSIVE LOSS

(in thousands, except share and per share data)

(unaudited)

	Three Months Ended September 30,		Nine Months Ended September 30,	
	2018	2017	2018	2017
Revenue:				
Collaboration revenue	\$814	\$1,493	\$6,938	\$1,991
Grant revenue	130	138	972	820
Total revenue	944	1,631	7,910	2,811
Operating expenses:				
Research and development	7,399	5,018	22,187	14,625
General and administrative	2,696	2,502	8,354	8,364
Total operating expenses	10,095	7,520	30,541	22,989
Loss from operations	(9,151)	(5,889)	(22,631)	(20,178)
Other income (expense):				
Interest and other income	362	113	890	245
Interest and other expense	(222)	(58)	(645)	(193)
Net loss	(9,011)	(5,834)	(22,386)	(20,126)
Change in unrealized loss on investments	(10)	—	(6)	—
Comprehensive loss	\$(9,021)	\$(5,834)	\$(22,392)	\$(20,126)
Net loss	\$(9,011)	\$(5,834)	\$(22,386)	\$(20,126)
Accretion of redeemable convertible preferred stock to redemption value	—	—	—	(5)
Net loss available to common stockholders	\$(9,011)	\$(5,834)	\$(22,386)	\$(20,131)